The Effects of Intravitreal Ozurdex Implant in DME

Nune Eye Hospital, Seoul, Korea20 enrolled

Overview

Intravitreal Ozurdex implant therapy improves visual outcome and OCT findings. The purpose of this study is that these results are correlated with the change of cytokine level known to be increased in DME patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetic Macular Edema

Interventions

Ozurdex intravitreal injectionDRUG

1. Ozurdex intravitreal injection and Antreior Chamber(AC) paracentesis at baseline 2. AC paracentesis at 6 wk 3. intravitreal Ozurdex injection and AC paracentesis at 18wk or 24wk

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: The patients of Type 1 or Type 2 Diabetes Mellitus fulfilling the following inclusion criteria shall be enrolled in the study: * Patients of Non Proliferative Diabetic Retinopathy(NPDR) with clinically significant macular edema(CSME) * Patients with Proliferative Diabetic Retinopathy(PDR) with CSME where proliferative component has been adequately treated with laser photocoagulation * Diabetic patients with cystoids macular edema * Minimum central thickness on OCT not less than 300 microns * BCVA 20/30\~20/320 Exclusion Criteria: * Patients with history of Anti-VEGF or steroid injection, any type of laser treatments, vitrectomy, cataract surgery within 6 months * Patients with history of ocular hypertension or glaucoma * Patients with media haze or pupillary non-dilation that does not allow good fundus photography, FFA and OCT * Patients with macular ischemia on FFA * Patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva * Patients whose posterior lens capsule is not intact. * patients with known hypersensitivity to any components of this product. * patients with vitreous hemorrhage * patients who have systemic treatment effect on study results * patients who enrolled other clinical study

Locations (1)

Nune Eye Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Changes of Central foveal thickness(CFT, height in micrometers)

Time frame: Baseline, 1 week, 6 weeks, 12 weeks, 18 weeks, 24 weeks

Secondary Outcomes

Changes of aqueous humor cytokine (VFGF, IL-2, IL-6,IL-8, MCP-1)

Time frame: Baseline, 6 weeks, 18 weeks

Changes of Best corrected Visual acuity(BCVA, ETDRS scale)

Time frame: Baseline, 1 week, 6 weeks, 12 weeks, 18 weeks, 24 weeks

Central Contacts

Oh Woong Kwon, MD, Ph D

CONTACT

+82+2+2086+7752 owkwon0301@yuhs.ac

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.